UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

Journal of clinical pharmacy and therapeutics, 2018-12, Vol.43 (6), p.906-909

2018

Volltextzugriff (PDF)

Eosinophilia secondary to lenalidomide therapy

Journal of clinical pharmacy and therapeutics, 2018-04, Vol.43 (2), p.273-275

2018

Volltextzugriff (PDF)

Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes

International journal of clinical practice (Esher), 2016-02, Vol.70 (2), p.156-162

2016

Volltextzugriff (PDF)

Drug cost avoidance in clinical trials of breast cancer

Journal of oncology pharmacy practice, 2019-07, Vol.25 (5), p.1099-1104

2019

Volltextzugriff (PDF)

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co‐administration

Journal of clinical pharmacy and therapeutics, 2016-08, Vol.41 (4), p.444-446

2016

Volltextzugriff (PDF)

Impact of the endorse study results on thromboprophylaxis prescribing patterns in medical patients attending the Emergency Department

International journal of clinical practice (Esher), 2015-01, Vol.69 (1), p.81-86

2015

Volltextzugriff (PDF)

The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital

Journal of clinical pharmacy and therapeutics, 2014-08, Vol.39 (4), p.376-382

2014

Volltextzugriff (PDF)

Validation of a method for recording pharmaceutical interventions

Journal of clinical pharmacy and therapeutics, 2012-08, Vol.37 (4), p.459-463

2012

Volltextzugriff (PDF)

Failure mode and effects analysis to improve quality in clinical trials

Journal of healthcare quality research, 2018-01, Vol.33 (1), p.33

2018

Volltextzugriff (PDF)

Implementation of an enhanced recovery after surgery program including a patient school: Impact on quality of life results

Injury, 2022-12, Vol.53 (12), p.3987-3992

2022

Volltextzugriff (PDF)

Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?

Expert opinion on orphan drugs, 2016-12, Vol.4 (12), p.1199-1206

2016

Volltextzugriff (PDF)

PP-026 Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report

European journal of hospital pharmacy. Science and practice, 2017-03, Vol.24 (Suppl 1), p.A213-A213

2017

Volltextzugriff (PDF)

PS-063 Medication label design and patient safety: An interactive comparison test

European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A241-A241

2016

Volltextzugriff (PDF)

PP-037 Risk of microbial contamination of pharmacy sterile preparations: A risk based decision matrix

European journal of hospital pharmacy. Science and practice, 2016-03, Vol.23 (Suppl 1), p.A210-A210

2016

Volltextzugriff (PDF)

5PSQ-148 TANDEM project: transitions of care and medication reconciliation in high-risk patients

European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A204-A204

2022

Volltextzugriff (PDF)

5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implementation and safety outcomes reported

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A151-A152

2023

Volltextzugriff (PDF)

4CPS-013 Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease: efficacy and safety

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A180-A180

2023

Volltextzugriff (PDF)

2SPD-007 Use of drugs in special situations

European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A173-A173

2023

Volltextzugriff (PDF)

4CPS-104 Persistence with disease-modifying therapy in multiple sclerosis patients

European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A63-A63

2022

Volltextzugriff (PDF)

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice

Clinical and experimental rheumatology, 2013-07, Vol.31 (4), p.559

2013

Volltextzugriff (PDF)

Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents

European journal of cancer care, 2017-05, Vol.26 (3), p.e12463-n/a

2017

Volltextzugriff (PDF)

DI-029 Use of erythropoiesis-stimulating agents after the cessation of supply of continuous erythropoietin receptor activator

European journal of hospital pharmacy. Science and practice, 2014-03, Vol.21 (Suppl 1), p.A81-A82

2014

Volltextzugriff (PDF)

DI-031 Effectiveness and safety of abiraterone in prostate cancer in clinical practice

European journal of hospital pharmacy. Science and practice, 2014-03, Vol.21 (Suppl 1), p.A82-A82

2014

Volltextzugriff (PDF)

DI-030 Prescription profile of abiraterone in metastatic prostate carcinoma

European journal of hospital pharmacy. Science and practice, 2014-03, Vol.21 (Suppl 1), p.A82-A82

2014

Volltextzugriff (PDF)

3PC-040 Galenic validation of a dexamethasone 0.01% mouthwash solution to prevent everolimus related stomatitis

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A40-A41

2020

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(121)

Publikationsform

Artikel
(163)
Berichte
(4)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice

Eosinophilia secondary to lenalidomide therapy

Optimisation of antithrombotic therapy in patients with acute coronary syndrome to reduce bleeding episodes

Drug cost avoidance in clinical trials of breast cancer

Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co‐administration

Impact of the endorse study results on thromboprophylaxis prescribing patterns in medical patients attending the Emergency Department

The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital

Validation of a method for recording pharmaceutical interventions

Failure mode and effects analysis to improve quality in clinical trials

Implementation of an enhanced recovery after surgery program including a patient school: Impact on quality of life results

Individualized therapy in patients with Fabry disease: is it a feasible strategy for rare diseases?

PP-026 Intranasal bevacizumab treatment on epistaxis in hereditary haemorrhagic telangiectasia: a case report

PS-063 Medication label design and patient safety: An interactive comparison test

PP-037 Risk of microbial contamination of pharmacy sterile preparations: A risk based decision matrix

5PSQ-148 TANDEM project: transitions of care and medication reconciliation in high-risk patients

5PSQ-119 A new pharmaceutical care programme for COVID-19 patients treated with Paxlovid®: Implementation and safety outcomes reported

4CPS-013 Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease: efficacy and safety

2SPD-007 Use of drugs in special situations

4CPS-104 Persistence with disease-modifying therapy in multiple sclerosis patients

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice

Pharmacotherapy follow‐up of key points in the safety of oral antineoplastic agents

DI-029 Use of erythropoiesis-stimulating agents after the cessation of supply of continuous erythropoietin receptor activator

DI-031 Effectiveness and safety of abiraterone in prostate cancer in clinical practice

DI-030 Prescription profile of abiraterone in metastatic prostate carcinoma

3PC-040 Galenic validation of a dexamethasone 0.01% mouthwash solution to prevent everolimus related stomatitis

Suchergebnisse filtern